6 days Ago By ABMN Staff
Alliancebernstein L.P. trimmed its position in shares of Teva Pharmaceutical Industries Limited ( NYSE:TEVA – Free Report ) by 9.
4% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 175,428 shares of the company’s stock after selling 18,274 shares during the period. Alliancebernstein L.
P.’s holdings in Teva Pharmaceutical Industries were worth $3,866,000 at the end of the most recent quarter. Several other hedge funds have also recently bought and sold shares of the company.
Wilmington Savings Fund Society FSB acquired a new stake in shares of Teva Pharmaceutical Industries during the 3rd quarter worth approximately $50,000. Ameliora Wealth Management Ltd. bought a new stake in Teva Pharmaceutical Industries during the fourth quarter worth $66,000.
IFP Advisors Inc boosted its holdings in shares of Teva Pharmaceutical Industries by 96.1% in the 4th quarter. IFP Advisors Inc now owns 3,999 shares of the company’s stock valued at $88,000 after purchasing an additional 1,960 shares in the last quarter.
C2P Capital Advisory Group LLC d.b.a.
Prosperity Capital Advisors bought a new position in shares of Teva Pharmaceutical Industries in the 4th quarter valued at $104,000. Finally, Assetmark Inc. raised its holdings in shares of Teva Pharmaceutical Industries by 1,370.
3% during the 4th quarter. Assetmark Inc. now owns 5,205 shares of the company’s stock worth $115,000 after buying an additional 4,851 shares in the last quarter.
54.05% of the stock is owned by institutional investors. Analyst Ratings Changes Several analysts recently weighed in on the company.
Barclays reduced their price objective on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating on the stock in a research note on Thursday, January 30th.
StockNews.com downgraded shares of Teva Pharmaceutical Industries from a “buy” rating to a “hold” rating in a research note on Monday. Piper Sandler upped their price objective on shares of Teva Pharmaceutical Industries from $23.
00 to $30.00 and gave the stock an “overweight” rating in a research report on Friday, January 17th. UBS Group cut their target price on shares of Teva Pharmaceutical Industries from $30.
00 to $27.00 and set a “buy” rating on the stock in a research report on Thursday, January 30th. Finally, Bank of America lowered their price target on shares of Teva Pharmaceutical Industries from $23.
00 to $20.00 and set a “buy” rating for the company in a report on Thursday, March 6th. Two research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock.
Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $23.43.
Teva Pharmaceutical Industries Stock Performance Shares of Teva Pharmaceutical Industries stock opened at $13.58 on Tuesday. The stock has a market cap of $15.
40 billion, a price-to-earnings ratio of -9.37, a P/E/G ratio of 1.44 and a beta of 0.
72. The company has a quick ratio of 0.75, a current ratio of 0.
98 and a debt-to-equity ratio of 2.97. Teva Pharmaceutical Industries Limited has a twelve month low of $12.
47 and a twelve month high of $22.80. The company’s fifty day moving average is $15.
71 and its 200 day moving average is $17.79. Teva Pharmaceutical Industries ( NYSE:TEVA – Get Free Report ) last released its quarterly earnings results on Wednesday, January 29th.
The company reported $0.70 EPS for the quarter, beating analysts’ consensus estimates of $0.69 by $0.
01. Teva Pharmaceutical Industries had a positive return on equity of 42.46% and a negative net margin of 9.
91%. Sell-side analysts forecast that Teva Pharmaceutical Industries Limited will post 2.5 EPS for the current year.
About Teva Pharmaceutical Industries ( Free Report ) Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. Read More Want to see what other hedge funds are holding TEVA? Visit HoldingsChannel.
com to get the latest 13F filings and insider trades for Teva Pharmaceutical Industries Limited ( NYSE:TEVA – Free Report ). Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter .
.
